The primary objective of the Cell & Tissue Models Core (Core B) is supporting the CF drug discovery efforts of participating investigators by providing state-of-the-art, CF-relevant cell and tissue models. More than 20 projects described in this renewal will utilize Core B for cell and/or tissue models. These models are used in high throughput screening assays, testing of lead compounds, therapeutically relevant preclinical bioassays, and translational science investigations of CF and airway pathophysiology. The Cell & Tissues Core achieves its objective via an infrastructure for the collection of CF-relevant tissues; instrumentation and expertise for cell isolation, culture, storage and quality control; adaptation and development of novel cell culture methods; and convenient distribution of cell models and tissues to CF investigators. Highly differentiated planar cell models of respiratory tract surface epithelial cells and submucosal gland cells that replicate native ion transport, airway surface liquid formation and mucin secretion remain the major cell model provided by the Core. In addition to our long-established strength in providing these models, the core has developed expertise in three-dimensional organotypic models (organoids), rotary wall vessel bioreactor cultures and conditionally reprogrammed cells. Organoids and rotary wall vessel bioreactor cultures provide a tissue-like environment that encourages cellular differentiation. Both methods increase the number of culture units available per tissue sample potentially generating more efficient, disease-relevant models for drug discovery. Conditionally reprogrammed cells allow expansion of CF cells through serial passaging allowing increased production of CF cell models and development of more efficient assays for evaluating small molecules. Using conditional reprogramming for producing more cell models from limited numbers of cells exhibiting rare CF genotypes will aid the development of ?personalized? therapies.

Public Health Relevance

Discovery of effective drugs to treat cystic fibrosis (CF) and its complications remains critical to improve and extend patient's lives. The major objective of Core B (Cell & Tissue Models Core) of the UCSF CF Research and Translation Center is to provide CF-relevant cell cultures for development of effective high throughput screening assays and cell and tissue models to verify effectiveness of candidate drugs. An additional goal of the Core is to improve cell models for CF drug discovery as well as hypothesis-driven research pursuing new therapeutic strategies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
2P30DK072517-11
Application #
8875428
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
2015-07-15
Budget End
2016-05-31
Support Year
11
Fiscal Year
2015
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94118
Sun, Dingyuan I; Tasca, Alexia; Haas, Maximilian et al. (2018) Na+/H+ Exchangers Are Required for the Development and Function of Vertebrate Mucociliary Epithelia. Cells Tissues Organs :1-14
Bhakta, Nirav R; Christenson, Stephanie A; Nerella, Srilaxmi et al. (2018) IFN-stimulated Gene Expression, Type 2 Inflammation, and Endoplasmic Reticulum Stress in Asthma. Am J Respir Crit Care Med 197:313-324
Smith, Alex J; Verkman, Alan S (2018) The ""glymphatic"" mechanism for solute clearance in Alzheimer's disease: game changer or unproven speculation? FASEB J 32:543-551
Duan, Tianjiao; Smith, Alex J; Verkman, Alan S (2018) Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica. J Neuroinflammation 15:294
Lee, Sujin; Cil, Onur; Diez-Cecilia, Elena et al. (2018) Nanomolar-Potency 1,2,4-Triazoloquinoxaline Inhibitors of the Kidney Urea Transporter UT-A1. J Med Chem 61:3209-3217
Tradtrantip, Lukmanee; Felix, Christian M; Spirig, Rolf et al. (2018) Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental in vitro and rat models of neuromyelitis optica. Neuropharmacology 133:345-353
Phuan, Puay-Wah; Veit, Guido; Tan, Joseph-Anthony et al. (2018) ?F508-CFTR Modulator Screen Based on Cell Surface Targeting of a Chimeric Nucleotide Binding Domain 1 Reporter. SLAS Discov 23:823-831
Verkman, Alan S; Yao, Xiaoming; Smith, Alex J (2018) The evolving mystery of why skeletal muscle is spared in seropositive neuromyelitis optica. J Cell Mol Med 22:2039-2040
Tradtrantip, Lukmanee; Yao, Xiaoming; Su, Tao et al. (2017) Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica. Acta Neuropathol 134:35-44
Tradtrantip, Lukmanee; Jin, Bjung-Ju; Yao, Xiaoming et al. (2017) Aquaporin-Targeted Therapeutics: State-of-the-Field. Adv Exp Med Biol 969:239-250

Showing the most recent 10 out of 276 publications